We are live on ! Find out more

672 hedge funds and large institutions have $13.7B invested in Sanofi in 2023 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 248 increasing their positions, 229 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more call options, than puts

Call options by funds: $99.3M | Put options by funds: $65.6M

8% more repeat investments, than reductions

Existing positions increased: 248 | Existing positions reduced: 229

0% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 61

1% less funds holding

Funds holding: 678672 (-6)

1.27% less ownership

Funds ownership: 21.41%20.13% (-1.3%)

5% less capital invested

Capital invested by funds: $14.5B → $13.7B (-$779M)

14% less funds holding in top 10

Funds holding in top 10: 1412 (-2)

Holders
672
Holders Change
-6
Holders Change %
-0.88%
% of All Funds
10.55%
Holding in Top 10
12
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-14.29%
% of All Funds
0.19%
New
61
Increased
248
Reduced
229
Closed
61
Calls
$99.3M
Puts
$65.6M
Net Calls
+$33.7M
Net Calls Change
-$7.24M

SNY Hedge Fund Activity: Q2 2023 in Review

672 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q2 2023, worth a combined $13.7B — down 5.4% from $14.5B a quarter earlier.

Fund positioning in SNY was balanced in Q2 2023: 61 funds opened new positions, 61 closed out, 248 added to existing stakes and 229 trimmed.

The largest buyer was Bank of New York Mellon, adding an estimated $69M. The largest seller was Boston Partners, cutting an estimated $260M.

  • 672 institutional investors held Sanofi (SNY) as of Q2 2023, down from 678 in Q1 2023.
  • Funds reported $13.7B of Sanofi stock for Q2 2023, down 5.4% quarter-over-quarter.
  • 61 funds opened new Sanofi positions in Q2 2023 and 61 closed out, a net change of 0 holders.
  • The largest Sanofi buyer in Q2 2023 was Bank of New York Mellon, an estimated $69M added.
  • The largest Sanofi seller in Q2 2023 was Boston Partners, an estimated $260M sold.

Based on aggregated 13F filings for Q2 2023.